Aerie Pharmaceuticals is a company that specializes in the development of pharmaceutical products for the treatment of glaucoma and other eye diseases. Its most promising products are Rhopressa and Roclatan, both of which are once-daily eye drops that reduce intraocular pressure in patients with glaucoma or ocular hypertension. Rhopressa is currently in Phase III registration trials, while Roclatan has completed a Phase IIb clinical trial in patients with open-angle glaucoma and ocular hypertension. The company is focused on bringing these innovative therapies to market, with the ultimate goal of improving the lives of those suffering from these conditions.